GB2597286A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with Jeavon’s syndrome is provided. In particular the seizures associated with Jeavon’s syndrome are: absence, myoclonic-absence, myoclonic and focal seizures with secondary generalisation. Preferably…
USPTO Abstract
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with Jeavon’s syndrome is provided. In particular the seizures associated with Jeavon’s syndrome are: absence, myoclonic-absence, myoclonic and focal seizures with secondary generalisation. Preferably the CBD preparation comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabidiol (THC). The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AEDs) selected from the group consisting of: valproic acid, clobazam, lamotrigine, zonisamide and ethosuximide. Preferably the dose of CBD is greater than 5 mg/kg/day, in particular the dose of CBD is selected from 20 mg/kg/day, 25 mg/kg/day or 50 mg/kg/day.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.